- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- UT-15C SR
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 15 Years to 80 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Tucson, Arizona • St Louis, Missouri + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Critical Limb Ischemia
- Interventions
- treprostinil dienthanolmine sustained release, Placebo
- Drug
- Lead sponsor
- Ochsner Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Critical Limb Ischemia
- Interventions
- UT-15C SR (treprostinil diethanolamine) 1mg oral tablets
- Drug
- Lead sponsor
- Southern Arizona Vascular Institute
- Other
- Eligibility
- 45 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 2
- States / cities
- Tucson, Arizona • Springfield, Illinois
- Conditions
- Pulmonary Arterial Hypertension, Interstitial Lung Disease, Healthy Adults
- Interventions
- Treprostinil, Right Heart Catheterization (RHC) while exercising, Optional Muscle Biopsy
- Drug · Diagnostic Test
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Treprostinil, Non-Treprostinil PAH Medications
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Timeline
- 2019
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Santa Barbara, California + 7 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- UT-15C SR, treprostinil diethanolamine
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Healthy Volunteers
- Interventions
- Treprostinil Palmitil Inhalation Powder, Placebo
- Drug
- Lead sponsor
- Insmed Incorporated
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Hypertension, Pulmonary, Pulmonary Arterial Hypertension
- Interventions
- Treprostinil diethanolamine, Esomeprazole
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Pulmonary Hypertension, Pulmonary Fibrosis
- Interventions
- Oral treprostinil
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 79 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 4 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Not listed
- Lead sponsor
- Jeffrey A. Feinstein
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Systemic Sclerosis
- Interventions
- treprostinil diethanolamine
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 19 more
- Conditions
- Systemic Sclerosis, Calcinosis
- Interventions
- Oral treprostinil
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Persistent Pulmonary Hypertension of the Newborn
- Interventions
- IV Remodulin, Placebo
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 1 Hour to 14 Days
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 14
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 11 more
- Conditions
- Congenital Heart Disease
- Interventions
- Treprostinil, Placebo
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Peripheral Vascular Disease
- Interventions
- Remodulin (treprostinil sodium) Injection
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003
- U.S. locations
- 4
- States / cities
- Springfield, Illinois • Worcester, Massachusetts • Albany, New York + 1 more
- Conditions
- Healthy Volunteers
- Interventions
- C16TR, Placebo, Tyvaso®
- Drug
- Lead sponsor
- Insmed Incorporated
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Ischemia Reperfusion Injury, Delayed Graft Function
- Interventions
- Treprostinil
- Drug
- Lead sponsor
- Rhode Island Hospital
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis
- Interventions
- Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer
- Drug · Device
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 1,850 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 84
- States / cities
- Birmingham, Alabama • Franklin, Arizona • Phoenix, Arizona + 69 more
- Conditions
- Critical Limb Ischemia, Peripheral Vascular Disease, Foot Ulcers, Rest Leg Pain
- Interventions
- Remodulin® (treprostinil sodium) Injection
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 7
- States / cities
- Tampa, Florida • Worcester, Massachusetts • Minneapolis, Minnesota + 4 more
- Conditions
- Single Ventricle
- Interventions
- Treprostinil
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- UT-15C (treprostinil diolamine)
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 471 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 38
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fresno, California + 33 more
- Conditions
- Hypertension, Pulmonary, Pulmonary Arterial Hypertension
- Interventions
- Treprostinil diethanolamine, Standardized meals
- Drug · Other
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Primary Pulmonary Hypertension
- Interventions
- LIQ861 Inhaled Treprostinil
- Drug
- Lead sponsor
- Liquidia Technologies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 19 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- L606 (Liposomal Treprostinil) Inhalation Solution 51ug, L606 Inhalation System, Placebo Solution
- Drug · Device · Other
- Lead sponsor
- Pharmosa Biopharm Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Austin, Texas